window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oncology

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Faeth Therapeutics focuses on PIKTOR as oncology Phase 2 data nears

    Faeth Therapeutics has launched as a publicly traded oncology company [...]

    June 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy

    Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

    June 15, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer

    Context Therapeutics has reported encouraging interim Phase 1 data for [...]

    June 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon reports strong early AML response data from iadademstat combinations at EHA 2026

    oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]

    June 11, 2026
  • Digital & Data,Drug Discovery & Development

    Sygnature Discovery partners with DaltonTx to expand AI drug discovery capabilities

    Sygnature Discovery has entered into a strategic collaboration with AI [...]

    June 11, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg presents preclinical POLB 001 data at EHA Congress

    Poolbeg Pharma has presented two posters at the European Hematology [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg begins patient recruitment for POLB 001 TOPICAL trial

    Poolbeg Pharma has activated the first clinical site and begun [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    PhoreMost advances brain cancer candidate PMC-001 towards Phase 1

    PhoreMost has unveiled its lead oncology programme, PMC-001, as the [...]

    June 11, 2026
  • Biotech & Pharma Business,Drug Discovery & Development

    AmMax licenses Lonza ADC technology for AML programme

    AmMax Bio has licensed antibody-drug conjugate technology from Lonza to [...]

    June 10, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Phase 3 data support PSMA-targeted radiopharmaceutical combination approach in advanced prostate cancer

    Phase 3 data presented at ASCO 2026 suggest a PSMA-targeted [...]

    June 6, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top